open access

Vol 52, No 6 (2021)
Editorial
Submitted: 2021-11-08
Accepted: 2021-12-06
Get Citation

Therapeutic drug monitoring: a key point in optimal treatment of invasive fungal disease

Jan Styczyński1
DOI: 10.5603/AHP.2021.0098
·
Acta Haematol Pol 2021;52(6):526-527.
Affiliations
  1. Department of Pediatric Hematology and Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Jurasz University Hospital 1, Bydgoszcz, Poland

open access

Vol 52, No 6 (2021)
EDITORIAL
Submitted: 2021-11-08
Accepted: 2021-12-06

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

hematology, hematooncology

About this article
Title

Therapeutic drug monitoring: a key point in optimal treatment of invasive fungal disease

Journal

Acta Haematologica Polonica

Issue

Vol 52, No 6 (2021)

Article type

Editorial

Pages

526-527

Page views

2896

Article views/downloads

132

DOI

10.5603/AHP.2021.0098

Bibliographic record

Acta Haematol Pol 2021;52(6):526-527.

Keywords

hematology
hematooncology

Authors

Jan Styczyński

References (10)
  1. Lehrnbecher T, Averbuch D, Castagnola E, et al. 8th European Conference on Infections in Leukaemia, 8th European Conference on Infections in Leukaemia. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021; 22(6): e254–e269.
  2. Gil L, Kałwak K, Piekarska A, et al. Antifungal management in adults and children with hematological malignancies or undergoing hematopoietic cell transplantation: recommendations of Polish Society of Hematology and Blood Transfusion, Polish Society of Pediatric Oncology and Hematology, and Polish Adult Leukemia Study Group, 2020. Acta Haematol Pol. 2020; 51(2): 60–72.
  3. Styczyński J, Czyżewski K, Ussowicz M, et al. Antimicrobial prophylaxis in patients after hematopoietic cell transplantation: results of a survey of the Polish Federation of Bone Marrow Transplant Centers. Acta Haematol Pol. 2020; 51(3): 183–186.
  4. Styczyński J, Czyżewski K, Ussowicz M, et al. Antimicrobial prophylaxis in patients after hematopoietic cell transplantation: results of a survey of the Polish Federation of Bone Marrow Transplant Centers. Acta Haematol Pol. 2020; 51(3): 183–186.
  5. Styczyński J, Piekarska A, Zaucha-Prażmo A, et al. Antimicrobial prophylaxis in adults and children undergoing hematopoietic cell transplantation: 2021 Polish recommendations. Acta Haematol Pol. 2021; 52(6): XXX–XXX.
  6. Liszka K, Resztak M, Zalewska P, et al. Therapeutic drug monitoring of posaconazole for effective prophylaxis of invasive fungal infections in pediatric patients. A pilot study. Acta Haematol Pol. 2021; 52(6): XXX–XXX.
  7. Luong ML, Al-Dabbagh M, Groll AH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016; 71(7): 1786–1799.
  8. Styczyński J. Infectious complications in children and adults with hematological malignancies. Acta Haematol Pol. 2019; 50(3): 167–173.
  9. Styczyński J, Czyżewski K, Frączkiewicz J, et al. Clinical spectrum and outcome of invasive mucormycosis in children and adults: Polish experience of the decade 2010–2019. Acta Haematol Pol. 2020; 51(3): 157–163.
  10. Giebel S, Basak G, Bieniaszewska M, et al. Current status and progress of Polish hemato-oncology. Acta Haematol Pol. 2021; 52(1): 4–17.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via Medica Publishers

ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone +48 58 320 94 94, fax+48 58 320 94 60,

e-mail: journals@viamedica.pl